Secondary Logo

Journal Logo

Hepatitis C Prevalence Among HIV-Positive MSM in San Francisco: 2004 and 2008

Raymond, H. Fisher MPH*; Hughes, Alison MPH*; O'Keefe, Kara PhD, MPH; Stall, Ron D. PhD, MPH; McFarland, Willi MD, PhD, MPH*

Sexually Transmitted Diseases: March 2011 - Volume 38 - Issue 3 - p 219-220
doi: 10.1097/OLQ.0b013e3181f68ed4
Note
Free

Recent reports suggest the potential for an epidemic of Hepatitis C among nonintravenous drug-using HIV-positive men who have sex with men. HIV-positive specimens from surveillance surveys in 2004 and 2008 were tested for HCV antibodies. Among noninjection drug using men who have sex with men, HCV prevalence was 8.7% and 4.5% in 2004 and 2008, respectively. There was no evidence of a change in HCV prevalence between 2004 and 2008.

Recent reports from Europe and New York suggest the potential for an epidemic of Hepatitis C among HIV-positive men who have sex with men (MSM) who are not intravenous drug users. HIV-positive specimens from behavioral surveillance surveys in 2004 (n = 92) and 2008 (n = 115) were tested for HCV antibodies and linked to injection drug use (IDU) and HCV diagnosis history. HCV antibodies were detected among 15.2% of HIV-positive MSM in 2004 and 8.3% of MSM in 2008. Among non-IDU MSM, HCV prevalence was 8.7% and 4.5% in 2004 and 2008, respectively. Most cases had been previously diagnosed, in 2004 (71.7%) and 2008 (94.0%). There was no evidence of a change in HCV prevalence between 2004 and 2008. HCV infection among HIV-positive MSM remains moderate-to-low among non-IDU MSM in San Francisco.

From the *San Francisco Department of Public Health, San Francisco, CA; †School of Public Health, University of California, Berkeley, CA; and ‡Graduate School of Public Health, University of Pittsburgh, PA.

Supported by NIMH R01MH077509 and CDC U62/CCU923549 and U62-PS000961.

Correspondence: Willi McFarland, MD, PhD, MPH, San Francisco Department of Public Health, HIV Epidemiology Section, 25 Van Ness Ave, Suite 500, San Francisco, CA 94102–6033. E-mail: willi_mcfarland@hotmail.com.

Received for publication June 28, 2010, and accepted August 8, 2010.

Reports from Europe and New York City have suggested a growing Hepatitus C Virus (HCV) epidemic among HIV-positive men who have sex with men (MSM).1,2 Furthermore, data indicate that sexual transmission may be the mechanism of HCV acquisition among noninjection drug using (IDU) MSM,3,4 in which case serosorting (i.e., unprotected anal sex between HIV-positive partners) may fuel HCV transmission.5 However, other studies from Seattle, San Diego, and New York City find low prevalence of HCV among non-IDU MSM.6 A sexually-driven epidemic of HCV among HIV-positive MSM could have significant impact on the health of HIV-positive MSM. We, therefore, assessed HCV prevalence and changes in HCV prevalence among HIV-positive MSM through serological testing of specimens collected during surveys conducted in 2004 and 2008.

As part of the US National HIV Behavioral Surveillance (NHBS) system, cross-sectional surveys of MSM were conducted in San Francisco in 2004 and in 2008, using a standardized time-location sampling protocol.7 Serum samples from those participants, who tested HIV-positive stored from the 2004 and 2008 survey rounds, were tested for HCV antibodies (Advia/Centaur HCV, Siemens Healthcare Diagnostics Inc, Deerfield, IL) at the San Francisco General Clinical Laboratory. Results were merged with behavioral data which included history of injection drug use and history of being diagnosed for HCV by a doctor or nurse. Point prevalence estimates were adjusted for the survey design; the change in prevalence from 2004 to 2008 was assessed using the χ2 test. We additionally examined mortality data from our local HIV/AIDS case registry to corroborate findings from our cross-sectional surveys. The NHBS protocols were reviewed and approved by the University of California, San Francisco Institutional Review Board; testing of the anonymous specimens for HCV antibody received nonresearch determination.

A total of 92 and 115 HIV-positive specimens from 2004 and 2008, respectively, were tested for HCV antibodies, including 69 and 82 non-IDU MSM, respectively. The prevalence of HCV among all HIV-positive MSM was 15.2% (95% confidence interval [CI], 7.7%–22.7%) in 2004 and 8.3% (95% CI, 1.9%–15.5%) in 2008, indicating no statistically significant change (P = 0.45). Limiting the sample to non-IDU MSM, HCV prevalence was 8.7% (95% CI, 1.9%–15.5%) and 4.5% (95% CI, 0.1%–8.9%) in 2004 and 2008, respectively. The apparent decline in HCV prevalence was not statistically significant (P = 0.33). Of note, few HCV infections appeared to be new; the majority of HCV-seropositive MSM provided a history of being previously diagnosed, both in 2004 (71.7%) and in 2008 (94.0%). Finally, 58% (95% CI, 46.0%–9.9%) and 55% (95% CI, 43.9–65.2) of non-IDU MSM reported engaging in unprotected anal intercourse in the past 6 months in 2004 and 2008, respectively. Stimulant use among these respondents was moderately high with 41% (95% CI, 28.7%–52.5%) and 26% (95% CI, 16.7%–35.5%) reporting use of stimulant drugs (i.e., methamphetamine, cocaine, crack) in 2004 and 2008, respectively.

HCV prevalence among HIV-positive MSM in San Francisco was moderately high overall and among non-IDU MSM, compared to the general US population prevalence of 1.3% to 1.9%.8 We found no evidence of a change in prevalence between 2004 and 2008, suggesting that HCV infection among HIV-positive MSM, even when engaging in sexual and/or substance use risks, in San Francisco does not yet follow the pattern among HIV-positive MSM in Europe and New York (Table 1). To further assess the apparent stabilization or possible decline in HCV prevalence, we examined mortality among MSM known to be living with HIV with and without coinfection with HCV in our local HIV/AIDS case registry from 2001 to 2005 (the years for which mortality data are complete). Overall, mortality was higher among those coinfected: for IDU, the difference in an annual average mortality was 22% with HCV compared to 7% without HCV, and for non-IDU average annual mortality was 11% versus 7% with and without HCV, respectively (San Francisco Department of Public Health, unpublished data, 2010). These data suggest that some of the apparent stabilization may be attributed to excess mortality; however, the figures also suggest that the rate of new HCV infections was not high enough to replace deaths from past infections. The latter observation corroborates our community survey findings weighing against a recent rise in HCV incidence among HIV-positive MSM. We acknowledge the limitations of the small sample size of MSM and non-IDU MSM in our surveys. Strengths of the samples are that it follows the standardized surveillance methodology conducted in cities nationally and was community-recruited rather than originating from HIV or STD clinics.1,2,6 Thus, our approach may be more representative of MSM nationally and can be examined in other jurisdictions and tracked over time. We also note that the use of antibody as opposed to nucleic acid testing will likely result in an underestimation in the prevalence of HCV infection. Finally, although NHBS and our case registry data do not entirely overlap temporally, we do believe that this is an acceptable use of existing data to corroborate disease outcomes. Although a low and no apparent rise in HCV is reassuring for the present, a high level of surveillance vigilance, including nucleic acid testing, is needed to detect changes in the epidemiology of HCV among groups at risk for HIV, careful assessment of the modes of HCV transmission, as well as routine screening among persons in HIV care.

TABLE 1

TABLE 1

Back to Top | Article Outline

REFERENCES

1.Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviors. AIDS 2007; 21:983–991.
2.Kim JH, Psevdos G Jr, Suh J, et al. Co-infection of hepatitis B and hepatitis C in human immunodeficiency virus-infected patients in New York City, United States. World J Gastronenterol 2008; 14:6689–6693.
3.Browne R, Asboe Y, Gilleace Atkins M, et al. Increased numbers of actue hepatitis C infection in HIV positive homosexual men: Is sexual transmission feeding the increase? Sex Transm Infect 2003; 80:326–327. Doi 10.1136/sti. 2003.008532.
4.Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: The Swiss HIV Cohort Study. Clin Infect Dis 2005; 41:395–402.
5.Snowden J, Raymond HF, McFarland W. Prevalence of seroadaptive behaviors of men who have sex with men, San Francisco, 2004. Sex Transm Infect 2009; 85:469–476.
6.Buffington J, Murray PJ, Schlanger K, et al. Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs. Public Health Rep 2007; 122(suppl 2):63–67.
7.MacKellar D, Gallagher KM, Finlayson T, et al. Surveillance of HIV risk and prevention behaviors of men who have sex with men—a national application of venue based, time-space sampling. Public Health Rep 2007; 122(suppl 1):39–47.
8.Centers for Disease Control and Prevention. Viral Hepatitis Topics: Statistics and Surveillance. 2010. Available at: http://www.cdc.gov/hepatitis/statistics.htm. Accessed 16 April, 2010.
© Copyright 2011 American Sexually Transmitted Diseases Association